Cytovation AS
Cytovation is a biotech company dedicated to creating transformative medicines for cancer patients through novel peptide engineering that guides and stimulates the immune system to recognize and eradicate tumors. With over 15 years of cutting-edge research, the company focuses on developing first-in-class immunotherapies, including CyPep-1, a targeted tumor membrane immunotherapy. Cytovation's pipeline includes clinical trials for its innovative treatments, and it collaborates with various partners to advance its research and development efforts.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Targeted tumor membrane lytic peptide (clinical-stage lead asset)
A first-in-class membrane-targeting lytic peptide engineered to selectively disrupt tumor cell plasma membranes, release tumor antigens, promote an inflammatory microenvironment, and induce a tumor-specific immune response. Developed for both topical application (cutaneous lesions) and intratumoral injection for solid tumors.
Targeted tumor membrane lytic peptide (clinical-stage lead asset)
A first-in-class membrane-targeting lytic peptide engineered to selectively disrupt tumor cell plasma membranes, release tumor antigens, promote an inflammatory microenvironment, and induce a tumor-specific immune response. Developed for both topical application (cutaneous lesions) and intratumoral injection for solid tumors.
Services
Design and conduct of Phase I/II oncology and dermatology studies including dose-escalation, safety monitoring, and multicenter execution via CRO partnerships.
Execution of preclinical efficacy studies and toxicology assessments in tumor models to support IND/first-in-human trials.
Partnerships with pharmaceutical companies to evaluate combination regimens with PD-1 checkpoint inhibitors and other agents.
Design and conduct of Phase I/II oncology and dermatology studies including dose-escalation, safety monitoring, and multicenter execution via CRO partnerships.
Execution of preclinical efficacy studies and toxicology assessments in tumor models to support IND/first-in-human trials.
Partnerships with pharmaceutical companies to evaluate combination regimens with PD-1 checkpoint inhibitors and other agents.
Expertise Areas
- Tumor immunotherapy
- Peptide drug discovery and engineering
- Formulation development for topical and intratumoral delivery
- Preclinical efficacy and toxicology
Key Technologies
- Peptide therapeutics
- Membrane-active lytic peptides
- Immunogenic cell death / neoantigen release
- Topical cream formulation